Literature DB >> 29793153

Effects of Mg2+ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.

Nathan G Glasgow1, Madeleine R Wilcox1, Jon W Johnson2.   

Abstract

Memantine and ketamine are NMDA receptor (NMDAR) open channel blockers that are thought to act via similar mechanisms at NMDARs, but exhibit divergent clinical effects. Both drugs act by entering open NMDARs and binding at a site deep within the ion channel (the deep site) at which the endogenous NMDAR channel blocker Mg2+ also binds. Under physiological conditions, Mg2+ increases the IC50s of memantine and ketamine through competition for binding at the deep site. Memantine also can inhibit NMDARs after associating with a second site accessible in the absence of agonist, a process termed second site inhibition (SSI) that is not observed with ketamine. Here we investigated the effects of 1 mM Mg2+ on recovery from inhibition by memantine and ketamine, and on memantine SSI, of the four main diheteromeric NMDAR subtypes. We found that: recovery from memantine inhibition depended strongly on the concentration of memantine used to inhibit the NMDAR response; Mg2+ accelerated recovery from memantine and ketamine inhibition through distinct mechanisms and in an NMDAR subtype-dependent manner; and Mg2+ occupation of the deep site disrupted memantine SSI in a subtype-dependent manner. Our results support the hypothesis that memantine associates with, but does not inhibit at the second site. After associating with the second site, memantine can either slowly dissociate directly to the extracellular solution, or transit to the deep site, resulting in typical channel block. Memantine's relatively slow dissociation from the second site underlies the dependence of NMDAR recovery from inhibition on both memantine concentration and on Mg2+.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Channel block; Ketamine; Memantine; NMDA receptors

Mesh:

Substances:

Year:  2018        PMID: 29793153      PMCID: PMC6050087          DOI: 10.1016/j.neuropharm.2018.05.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  85 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.

Authors:  Shawn E Kotermanski; Jon W Johnson
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

3.  Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors.

Authors:  D J Wyllie; P Béhé; D Colquhoun
Journal:  J Physiol       Date:  1998-07-01       Impact factor: 5.182

4.  Actions of bupivacaine, a widely used local anesthetic, on NMDA receptor responses.

Authors:  Meaghan A Paganelli; Gabriela K Popescu
Journal:  J Neurosci       Date:  2015-01-14       Impact factor: 6.167

5.  Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles.

Authors:  Kevin Erreger; Shashank M Dravid; Tue G Banke; David J A Wyllie; Stephen F Traynelis
Journal:  J Physiol       Date:  2005-01-13       Impact factor: 5.182

6.  Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine.

Authors:  J G Dilmore; J W Johnson
Journal:  Biophys J       Date:  1998-10       Impact factor: 4.033

Review 7.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

Authors:  Chris G Parsons; Albrecht Stöffler; Wojciech Danysz
Journal:  Neuropharmacology       Date:  2007-08-10       Impact factor: 5.250

8.  Regulation of glycine-insensitive desensitization of the NMDA receptor in outside-out patches.

Authors:  G Tong; C E Jahr
Journal:  J Neurophysiol       Date:  1994-08       Impact factor: 2.714

9.  Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats.

Authors:  Shawn E Kotermanski; Jon W Johnson; Edda Thiels
Journal:  Pharmacol Biochem Behav       Date:  2013-05-08       Impact factor: 3.533

10.  Ionic permeability characteristics of the N-methyl-D-aspartate receptor channel.

Authors:  M M Zarei; J A Dani
Journal:  J Gen Physiol       Date:  1994-02       Impact factor: 4.086

View more
  9 in total

1.  MK801-induced locomotor activity in preweanling and adolescent male and female rats: role of the dopamine and serotonin systems.

Authors:  Sanders A McDougall; Matthew G Apodaca; Ginny I Park; Angie Teran; Timothy J Baum; Nazaret R Montejano
Journal:  Psychopharmacology (Berl)       Date:  2020-05-22       Impact factor: 4.530

2.  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Authors:  Andreea L Turcu; Júlia Companys-Alemany; Matthew B Phillips; Dhilon S Patel; Christian Griñán-Ferré; M Isabel Loza; José M Brea; Belén Pérez; David Soto; Francesc X Sureda; Maria G Kurnikova; Jon W Johnson; Mercè Pallàs; Santiago Vázquez
Journal:  Eur J Med Chem       Date:  2022-04-08       Impact factor: 7.088

3.  Inhibition of NMDA receptors through a membrane-to-channel path.

Authors:  Madeleine R Wilcox; Aparna Nigam; Nathan G Glasgow; Chamali Narangoda; Matthew B Phillips; Dhilon S Patel; Samaneh Mesbahi-Vasey; Andreea L Turcu; Santiago Vázquez; Maria G Kurnikova; Jon W Johnson
Journal:  Nat Commun       Date:  2022-07-15       Impact factor: 17.694

Review 4.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

5.  Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.

Authors:  Feng Yi; Subhrajit Bhattacharya; Charles M Thompson; Stephen F Traynelis; Kasper B Hansen
Journal:  J Physiol       Date:  2019-11-02       Impact factor: 5.182

6.  Effects of dopamine and serotonin synthesis inhibitors on the ketamine-, d-amphetamine-, and cocaine-induced locomotor activity of preweanling and adolescent rats: sex differences.

Authors:  Sanders A McDougall; Jasmine W Rios; Matthew G Apodaca; Ginny I Park; Nazaret R Montejano; Jordan A Taylor; Andrea E Moran; Jasmine A M Robinson; Timothy J Baum; Angie Teran; Cynthia A Crawford
Journal:  Behav Brain Res       Date:  2019-10-23       Impact factor: 3.332

Review 7.  Ketamine and the Future of Rapid-Acting Antidepressants.

Authors:  Lace M Riggs; Todd D Gould
Journal:  Annu Rev Clin Psychol       Date:  2021-02-09       Impact factor: 18.561

Review 8.  Distinct roles of GRIN2A and GRIN2B variants in neurological conditions.

Authors:  Scott J Myers; Hongjie Yuan; Jing-Qiong Kang; Francis Chee Kuan Tan; Stephen F Traynelis; Chian-Ming Low
Journal:  F1000Res       Date:  2019-11-20

Review 9.  Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.

Authors:  Songbai Xu; Xiaoxiao Yao; Bingjin Li; Ranji Cui; Cuilin Zhu; Yao Wang; Wei Yang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.